Advanced search
Publication Cover
Pharmacogenomics Volume 11, 2010 - Issue 1
Submit an article Journal homepage
336
Views
0
CrossRef citations to date
0
Altmetric
Technology Report

ARMS test for Diagnosis of CYP2C9 and VKORC1 Mutation in Patients with Pulmonary Embolism in Han Chinese

Jin Zhu1 Beijing Chao-Yang Hospital affiliated with Beijing Capital Medical University, 8 Gongtinanlu Street, Beijing, MA100020, China. Tel.: +86 108 523 1788 Fax: +86 108 523 [email protected]
,
Weijuan Zhang1 Beijing Chao-Yang Hospital affiliated with Beijing Capital Medical University, 8 Gongtinanlu Street, Beijing, MA100020, China. Tel.: +86 108 523 1788 Fax: +86 108 523 [email protected]
,
Yanyan Li1 Beijing Chao-Yang Hospital affiliated with Beijing Capital Medical University, 8 Gongtinanlu Street, Beijing, MA100020, China. Tel.: +86 108 523 1788 Fax: +86 108 523 [email protected]
,
Wei Zhang1 Beijing Chao-Yang Hospital affiliated with Beijing Capital Medical University, 8 Gongtinanlu Street, Beijing, MA100020, China. Tel.: +86 108 523 1788 Fax: +86 108 523 [email protected]
,
Heyao Wang1 Beijing Chao-Yang Hospital affiliated with Beijing Capital Medical University, 8 Gongtinanlu Street, Beijing, MA100020, China. Tel.: +86 108 523 1788 Fax: +86 108 523 [email protected]
,
Wenjie Zheng2 Beijing Institute of Technology, Beijing, China
&
Chen Wang1 Beijing Chao-Yang Hospital affiliated with Beijing Capital Medical University, 8 Gongtinanlu Street, Beijing, MA100020, China. Tel.: +86 108 523 1788 Fax: +86 108 523 [email protected]
 show all
Pages 113-119 | Published online: 18 Dec 2009

Bibliography

  • Cooper GM : A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose.Blood112(4) , 1022–1027 (2008).
  • Takeuchi F , McGinnisR, BourgeoisS et al.: A genome-wide association study confirms VKORC1, CYP2C9, and possibly CYP4F2 as principal genetic determinants of warfarin dose.PLoS Genet.5(3) , E1000433 (2009).
  • Wang T -L, Li H-L, Tjong W-Y et al.: Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin. Chim. Acta396(1–2) , 76–79 (2008).
  • Wadelius M , ChenLY, LindhJD et al.: The largest prospective warfarin-treated cohort supports genetic forecasting.Blood113(4) , 784–792 (2009).
  • Glurich I , BurmesterJK, ColdwellMD: Understanding the pharmacogenetic approach to warfarin dosing.Heart Fail. Rev. DOI 10.1007/s10741-008-9115-9 (2008) (Epub ahead of print).
  • Yin T , MiyataT: Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 – rationale and perspectives.Thromb. Res.120(1) , 1–10 (2007).
  • Rettie AE , TaiG: The pharmocogenomics of warfarin: closing in on personalized medicine.Mol. Interv.6(4) , 223–227 (2006).
  • Wadelius M , ChenLY, ErikssonN et al.: Association of warfarin dose with genes involved in its action and metabolism.Hum. Genet.121 , 23–34 (2007).
  • Zhu Y , ShennanM, ReynoldsKK et al.: Estimation of warfarin maintenance dose based on VKORC1 (-1639G>A) and CYP2C9 genotypes.Clin. Chem.53(7) , 1199–1205 (2007).
  • Yuan HY , ChenJJ, LeeMT et al.: A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.Hum. Mol. Genet.14(13) , 1745–1751 (2005).
  • Taube J , HalsallD, BaglinT: Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment.Blood96(5) , 1816–1819 (2000).
  • Si D , GuoY, ZhangY, YangL, ZhouH, ZhongD: Identification of a novel variant CYP2C9 allele in Chinese.Pharmacogenetics14(7) , 465–469 (2004).
  • Gage BF , LeskoLJ: Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.J. Thromb. Thrombolysis25(1) , 45–51 (2008).
  • Moridani M , FuL, SelbyR et al.: Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort.Clin. Biochem.39(6) , 606–612 (2006).
  • Sconce EA , KhanTI, WynneHA et al.: The impact of CYP2C9 and VKORC1 polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.Blood106(7) , 2329–2333 (2005).
  • Bodin L , BerstuyftC, TregouetDA et al.: Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.Blood106(1) , 135–140 (2005).
  • Aomori T , YamamotoK, Oguchi-KatayamaA et al.: Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2.Clin. Chem.55(4) , 804–812 (2009).
  • Mushiroda T , OhnishiY, SaitoS et al.: Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.J. Hum. Genet.51(3) , 249–253 (2006).
  • King C , Scott-HortonT: Pyrosequencing: a simple method for accurate genotyping.J. Vis. Exp. (11) , pii: 630. doi: 10.3791/630 (2008).
  • Newton CR , GrahamA, HeptinstallLE et al.: Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS).Nucleic Acids Res.17 , 2503–2516 (1989).
  • Little S : ARMS analysis of point mutations. In: Laboratory Methods for the Detection of Mutations and Polymorphisms in DNA. Taylor GR (Ed.). CRC Press, FL, USA 45–51 (1997).
  • Hayashi K , HashimotoN, DaigenM, AshikawaI: Development of PCR-based SNP markers for rice blast resistance genes at the Piz locus.Theor. Appl. Genet.108 , 1212–1220 (2004).
  • Luo X , XuK: A solid phase method for extracting DNA from whole blood.Chin. J. Clin. Lab. Sci.22(2) , 123–125 (2004).
  • Chou Q , RussellM, BirchDE, RaymondJ, BlochW: Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications.Nucleic Acids Res.20(7) , 1717–1723 (1992).
  • Sponer J , RileyKE, HobzaP: Nature and magnitude of aromatic stacking of nucleic acid bases.Phys. Chem. Chem. Phys.10(19) , 2595–2610 (2008).
  • Dzantiev L , RomanoLJ: A conformational change in E. coli DNA polymerase I (Klenow fragment) is induced in the presence of a dNTP complementary to the template base in the active site.Biochemistry39 , 356–361 (2000).
  • Kool ET : Replication of non-hydrogen bonded bases by DNA polymerases: a mechanism for steric matching.Biopolymers48(1) , 3–17 (1998).
  • Kool ET : Active site tightness and substrate fit in DNA replication.Annu. Rev. Biochem.71 , 191–219 (2002).
  • Kool ET : Hydrogen bonding, base stacking, and steric effects in DNA replication.Annu. Rev. Biophys. Biomol. Struct.30 , 1–22 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.